Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Nirvana Life Sciences Inc: Nirvana Life Sciences reinstated for trading | 1 | Stockwatch | ||
Fr | CSE Bulletin: Reinstatement - Nirvana Life Sciences Inc. (NIRV) | 207 | Newsfile | Toronto, Ontario--(Newsfile Corp. - le 20 décembre/December 2024) - Effective immediately, Nirvana Life Sciences Inc. will be reinstated for trading. The Company has rectified the situation... ► Artikel lesen | |
NIRVANA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
05.09. | Nirvana Life Sciences Inc: Nirvana Life Sciences suspended by CSE | 1 | Stockwatch | ||
05.09. | CSE Bulletin: Suspension - Nirvana Life Sciences Inc. (NIRV) | 69 | Newsfile | le 5 septembre/September 2024
Effective immediately, Nirvana Life Sciences Inc. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument... ► Artikel lesen | |
05.09. | Nirvana Life Sciences Inc: Nirvana Life Sciences halted at the open | 1 | Stockwatch | ||
29.01. | Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction | 595 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 29, 2024) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian-based life sciences company, is pleased to report... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TONIX PHARMACEUTICALS | 0,388 | -3,80 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
REVIVA PHARMACEUTICALS | 1,795 | +9,45 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
HARROW | 33,450 | -1,65 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 3,515 | -2,09 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
BRIGHT MINDS BIOSCIENCES | 37,250 | -3,72 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
PAINREFORM | 4,600 | +3,14 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
THERIVA BIOLOGICS | 1,690 | +29,01 % | Theriva Biologics, Inc.: Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer | ROCKVILLE, Md., Dec. 05, 2024the completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combination with gemcitabine/nab-paclitaxel as... ► Artikel lesen | |
NRX PHARMACEUTICALS | 1,530 | +7,75 % | NRX Pharmaceuticals-Vorsitzender Jonathan Javitt erwirbt Aktien für 46.800 US-Dollar | ||
ITERUM THERAPEUTICS | 1,740 | -2,25 % | Iterum Therapeutics PLC: Iterum Therapeutics Regains Full Nasdaq Compliance | DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections... ► Artikel lesen | |
OMNIAB | 3,520 | +0,86 % | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program... ► Artikel lesen | |
INHIBIKASE THERAPEUTICS | 3,020 | +2,03 % | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
VYNE THERAPEUTICS | 2,970 | +15,56 % | VYNE Therapeutics Inc.: VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor | Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable... ► Artikel lesen | |
ONKURE THERAPEUTICS | 7,890 | -3,55 % | Reneo Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 7,91 US-Dollar | ||
SUNSHINE BIOPHARMA | 3,220 | +7,33 % | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus | FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen |